• Lang Li, Tammy Sajdyk, SmithEllen M LEMLUniversity of Michigan, Ann Arbor, Michigan, USA., Chien Wei Chang, Claire Li, Richard H Ho, Raymond Hutchinson, Elizabeth Wells, Jodi L Skiles, Naomi Winick, Paul L Martin, and Jamie L Renbarger.
• Ohio State University, Columbus, Ohio, USA.
• Clin. Pharmacol. Ther. 2019 Jun 1; 105 (6): 1421-1428.

AbstractVincristine is one of the core chemotherapy agents used in the treatment of pediatric acute lymphoblastic leukemia (ALL). However, one of the major toxicities resulting from vincristine exposure is vincristine-induced peripheral neuropathy (VIPN). When VIPN results in significant morbidity, the vincristine dose may need to be reduced, thus potentially decreasing the effectiveness of treatment. To date, there are no robust biomarkers used clinically to determine which patients will be at risk for worse neuropathy. The current study included genomewide association study (GWAS) in two independent cohorts: Pediatric Oncology Group (POG) ALL trials and a multicenter study based at Indiana University in children with ALL. A meta-analysis of the cohorts identified two single-nucleotide polymorphisms (SNPs), rs1045644 and rs7963521, as being significantly (P value threshold 0.05/4749 = 1.05E-05) associated with neuropathy. Subsequently these SNPs may be effective biomarkers of VIPN in children with ALL.© 2018 The Authors Clinical Pharmacology & Therapeutics © 2018 American Society for Clinical Pharmacology and Therapeutics.

25 keywords...

hide…